PMID- 34300342
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210729
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 10
IP  - 14
DP  - 2021 Jul 19
TI  - Premedication Does Not Influence the Incidence of Infliximab Infusion Reactions 
      in Pediatric Patients with Inflammatory Bowel Disease-A Single Center 
      Case-Control Study.
LID - 10.3390/jcm10143177 [doi]
LID - 3177
AB  - BACKGROUND: Infusion reactions (IRs) are the most common adverse events (AEs) of 
      infliximab (IFX) treatment in patients with inflammatory bowel disease (IBD). 
      Prophylactic premedication (PM) with corticosteroids or antihistamines prior to 
      IFX infusions has been used in clinical practice, but its efficacy is not known. 
      The aim of this study was to assess the influence of steroid PM on IR incidence 
      in pediatric patients with IBD receiving IFX. METHODS: We performed a 
      case-control study that included pediatric patients with IBD receiving IFX. 
      Patients were divided into four subgroups according to the agent and PM they 
      received: Remicade (original drug) + PM, and two biosimilars-Reshma +/- PM, and 
      Flixabi-PM. At our site, until 2018, PM with steroids was used as a part of 
      standard IFX infusion (PM+); however, since then, this method has no longer been 
      administered (PM-). IRs were divided into mild/severe reactions. Differences 
      between subgroups were assessed with the appropriate chi-square test. 
      Multivariate logistic regression was used to assess associations between PM and 
      IR incidence, correcting for co-medication usage. RESULTS: There were 105 
      children (55 PM+, 44 male, mean age 15 years) included in the study who received 
      1276 infusions. There was no difference between the PM+ and PM- subgroups, either 
      in incidence of IR (18.2% vs. 16.0% of patients, p > 0.05) or in percentage of 
      infusions followed by IR (2.02% vs. 1.02% of infusions, p > 0.5). The OR of 
      developing IR when using PM was 0.34, and the difference in IRs ratio in PM+ and 
      PM- patients was not statistically significant (95% CI, 0.034-1.9). There were 
      11/18 (61.1%) severe IRs (anaphylactic shock) reported in all patients (both PM+ 
      and PM-). CONCLUSION: At our site, the incidence of IR was low, and PM did not 
      decrease the incidence of IR in pediatric patients with IBD receiving IFX. These 
      results indicate that PM with steroids should not be a standard part of IFX 
      infusion to prevent IR.
FAU - Szymanska, Edyta
AU  - Szymanska E
AD  - Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The 
      Childrens' Memorial Health Institute, 04-730 Warsaw, Poland.
FAU - Dadalski, Maciej
AU  - Dadalski M
AD  - Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The 
      Childrens' Memorial Health Institute, 04-730 Warsaw, Poland.
FAU - Sieczkowska-Golub, Joanna
AU  - Sieczkowska-Golub J
AUID- ORCID: 0000-0003-1381-0742
AD  - Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The 
      Childrens' Memorial Health Institute, 04-730 Warsaw, Poland.
FAU - Jarzebicka, Dorota
AU  - Jarzebicka D
AUID- ORCID: 0000-0002-3977-7541
AD  - Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The 
      Childrens' Memorial Health Institute, 04-730 Warsaw, Poland.
FAU - Meglicka, Monika
AU  - Meglicka M
AD  - Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The 
      Childrens' Memorial Health Institute, 04-730 Warsaw, Poland.
FAU - Osiecki, Marcin
AU  - Osiecki M
AD  - Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The 
      Childrens' Memorial Health Institute, 04-730 Warsaw, Poland.
FAU - Wiernicka, Anna
AU  - Wiernicka A
AD  - Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The 
      Childrens' Memorial Health Institute, 04-730 Warsaw, Poland.
FAU - Lebensztejn, Dariusz M
AU  - Lebensztejn DM
AD  - Department of Pediatrics, Gastroenterology, Hepatology, Nutrition and 
      Allergology, Medical University of Bialystok, 15-089 Bialystok, Poland.
FAU - Korczowski, Bartosz
AU  - Korczowski B
AUID- ORCID: 0000-0003-1626-1283
AD  - Department of Pediatrics and Pediatric Gastroenterology, College of Medical 
      Sciences, University of Rzeszow, 35-310 Rzeszow, Poland.
FAU - Kierkus, Jaroslaw
AU  - Kierkus J
AUID- ORCID: 0000-0003-2272-1581
AD  - Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The 
      Childrens' Memorial Health Institute, 04-730 Warsaw, Poland.
LA  - eng
PT  - Journal Article
DEP - 20210719
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC8303466
OTO - NOTNLM
OT  - inflammatory bowel disease
OT  - infliximab
OT  - infusion reaction
OT  - premedication
COIS- The authors declare no conflict of interest.
EDAT- 2021/07/25 06:00
MHDA- 2021/07/25 06:01
PMCR- 2021/07/19
CRDT- 2021/07/24 01:07
PHST- 2021/06/15 00:00 [received]
PHST- 2021/07/14 00:00 [revised]
PHST- 2021/07/15 00:00 [accepted]
PHST- 2021/07/24 01:07 [entrez]
PHST- 2021/07/25 06:00 [pubmed]
PHST- 2021/07/25 06:01 [medline]
PHST- 2021/07/19 00:00 [pmc-release]
AID - jcm10143177 [pii]
AID - jcm-10-03177 [pii]
AID - 10.3390/jcm10143177 [doi]
PST - epublish
SO  - J Clin Med. 2021 Jul 19;10(14):3177. doi: 10.3390/jcm10143177.